Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector

Truenat is a novel molecular assay that rapidly detects tuberculosis (TB) and rifampicin-resistance. Due to the portability of its battery-powered testing platform, it may be valuable in peripheral healthcare settings in India. Using a microsimulation model, we compared four TB diagnostic strategies...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2019-07, Vol.14 (7), p.e0218890
Hauptverfasser:	Lee, David J, Kumarasamy, Nagalingeswaran, Resch, Stephen C, Sivaramakrishnan, Gomathi N, Mayer, Kenneth H, Tripathy, Srikanth, Paltiel, A David, Freedberg, Kenneth A, Reddy, Krishna P
Format:	Artikel
Sprache:	eng
Schlagworte:	Accounting Adult Batteries Biology and Life Sciences Budgets Cost analysis Cost benefit analysis Costs Diagnosis Diagnostic systems Drug Resistance, Bacterial Economic aspects Expenditures Female Funding Health care Health Care Costs Health care facilities Health facilities HIV HIV Infections - diagnosis HIV Infections - microbiology HIV Infections - virology HIV tests Hospitals Human immunodeficiency virus Humans India - epidemiology Laboratories Life expectancy Life span Male Medical diagnosis Medical practices Medical schools Medicine and Health Sciences Microscopy Molecular diagnostic techniques Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - pathogenicity Novels Parameter sensitivity Patients People and Places Point of care testing Point-of-Care Systems Primary care Primary health care Public health Public Sector Rifampin Rifampin - adverse effects Rifampin - therapeutic use Sensitivity analysis Smear Social Sciences Sputum Sputum - microbiology Tuberculosis Tuberculosis - diagnosis Tuberculosis - drug therapy Tuberculosis - economics Tuberculosis - microbiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!